Clinical observation of pemetrexed on advanced non-small-cell lung cancer
详细信息 查看全文
- 作者：Yongfa Zheng (1)
Wei Ge (1)
Ling Zhang (1)
Zhenyu Zhao (1)
Fangfang Jie (1) - 关键词：non ; small ; cell lung cancer ; pemetrexed ; chemotherapy
- 刊名：The Chinese-German Journal of Clinical Oncology
- 出版年：2011
- 出版时间：March 2011
- 年：2011
- 卷：10
- 期：3
- 页码：140-143
- 全文大小：219KB
- 参考文献：1. Demarinis F, Paul S, Hanna N, / et al. Survival update for the phase III study of pemetrexed vs. docetaxel in non-small cell lung cancer (NSCLC). J Clin Oncol, 2006, 24: 397-97.
2. Hanan N, Shepherd FA, Fossella FV, / et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previous treated with chemotherapy. J Clin Oncol, 2004, 22:1589-597. CrossRef
3. Scagliotti GV, Parikh P, Von PJ, / et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol, 2008, 26: 3543-551. CrossRef
4. Therasse P, Arbuck SG, Eisenhauer EA, / et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst, 2000, 92: 205-16. CrossRef
5. Sun Y. Medical oncology. Beijing: People Health Press, 2001. 324-40.
6. Schiller JH, Harrington D, Belani CP, / et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 2002, 346: 92-8. CrossRef
7. Shih C, Chen VJ, Gossett LS, / et al. LY231514, a pyrrolo [2,3-d] pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res, 1997, 57: 1116-123.
8. Giorgio S, Nasser H, Frank F, / et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist, 2009, 14: 253-63. CrossRef
9. Syrigos KN, Vansteenkiste J, Parikh P, / et al. Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer. Ann Oncol, 2010, 21: 556-61. CrossRef
10. Ciuleanu TE, Brodowicz C, Belani CP, / et al. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study. J Clin Oncol, 2008, 26: 8011.
11. Peng G, Zinner RG, Wang Y, / et al. Comparison of patient outcomes stratified by histology among pemetrexed (P)-treated patients (pts) with stage IIIB/IV nonsmall cell lung cancer (NSCLC) in two phase II trials. J Clin Oncol, 2008, 26: 8096.
12. Blasco A, Sirera R, Terrasa J, / et al. Pemetrexed as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): Efficacy and correlation with molecular markers. J Clin Oncol, 2008, 26: 8095.
13. Itaya T, Yamaoto N, Ando M, / et al. Influence of histological type, smoking history and chemotherapy on survival after first-line therapy in patients with advanced non-small cell lung cancer. Cancer Sci, 2007, 98: 226-30. CrossRef
14. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers -a different disease. Nat Rev Cancer, 2007, 7: 778-90. CrossRef
15. Fujiwara Y, Kiura K, Toyooka S, / et al. Never-smoking history predicts long-term survival in patients with non-small cell lung cancer with postoperative recurrence. J Clin Oncol, 2006, 24: 20047. CrossRef
16. Gronberg BH, Bremnes RM, Flotten O, / et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol, 2009, 27:3217-224. CrossRef - 作者单位：Yongfa Zheng (1)
Wei Ge (1)
Ling Zhang (1)
Zhenyu Zhao (1)
Fangfang Jie (1)
1. Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, 430060, China
文摘
Objective The aim of our study was to observe the efficacy and toxicity of 50 cases of advanced non-small cell lung cancer (NSCLC) patients treated by pemetrexed. Methods Fifty patients, including 29 females and 21 males, with a median age 62 years (35-2 years), 13 of whom were treated with pemetrexed only and the left 37 cases were treated with pemetrexed combined with platinum in the Department of Oncology, Renmin Hospital of Wuhan University from June 2006 to March 2009. Single agent regimen: patients received pemetrexed 500 mg/m2 on day 1 with every 21 days. Combination regimen: patients received pemetrexed 500 mg/m2 on day 1 and carboplatin 300 mg/m2 on day 1 or cisplatin 35 mg/m2 on day 1 to day 3 or nedaplatin 80 mg/m2 on day 1 by intravenous infusion with 21 days as one cycle. RECIST 1.0 standard was used to evaluate the clinical efficiency, and the WHO toxicity standard was used to evaluate toxic reaction, and the QOL was used to evaluate the quality of life. Results All patients were given 162 cycles (at least 2 cycles, at most 6 cycles) and the response rate of all the patients were evaluated. There were 2 complete remission (CR), 7 partial remission (PR), 22 stable disease (SD) and 19 progressive disease (PD) in the group, the overall response rate was (RR) was 18.0% and disease control rate (DCR) 62.0%. The quality of life improvement rate reaches 58.0%. The major toxic reaction included neutropenia, thrombocytopenia, hypemia, nausea, and vomiting. Most of the severity of these effects was grade I–II and well tolerated. Conclusion Chemotherapy with pemetrexed or pemetrexed combined with platinum in the treatment of advanced non-small cell lung cancer is effective, safe and well-tolerable, which can improve quality of life of the patient.